ES2343681T3 - Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad. - Google Patents

Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad. Download PDF

Info

Publication number
ES2343681T3
ES2343681T3 ES03725109T ES03725109T ES2343681T3 ES 2343681 T3 ES2343681 T3 ES 2343681T3 ES 03725109 T ES03725109 T ES 03725109T ES 03725109 T ES03725109 T ES 03725109T ES 2343681 T3 ES2343681 T3 ES 2343681T3
Authority
ES
Spain
Prior art keywords
baselineskip
fviii
lrp
factor viii
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03725109T
Other languages
English (en)
Spanish (es)
Inventor
Koenraad Mertens
Arend Niels Bovenschen
Jan Voorberg
Manfred Rieger
Friedrich Scheiflinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Sanquin Bloedvoorziening
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Application granted granted Critical
Publication of ES2343681T3 publication Critical patent/ES2343681T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES03725109T 2002-04-29 2003-04-28 Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad. Expired - Lifetime ES2343681T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37635102P 2002-04-29 2002-04-29
US376351P 2002-04-29

Publications (1)

Publication Number Publication Date
ES2343681T3 true ES2343681T3 (es) 2010-08-06

Family

ID=29401334

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03725109T Expired - Lifetime ES2343681T3 (es) 2002-04-29 2003-04-28 Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad.

Country Status (10)

Country Link
US (1) US8586538B2 (2)
EP (1) EP1497330B1 (2)
JP (2) JP2005535588A (2)
AT (1) ATE463514T1 (2)
AU (1) AU2003227687B2 (2)
CA (1) CA2484155C (2)
DE (1) DE60332011D1 (2)
DK (1) DK1497330T3 (2)
ES (1) ES2343681T3 (2)
WO (1) WO2003093313A2 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006003183A1 (de) * 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
EP2297330A4 (en) * 2008-06-04 2012-03-14 Bayer Healthcare Llc FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND
PL2291523T3 (pl) 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
JP5394864B2 (ja) * 2009-09-10 2014-01-22 アスモ株式会社 モータ
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
JP6042335B2 (ja) 2010-09-15 2016-12-14 ノヴォ ノルディスク アー／エス 細胞取込みが低下した第ｖｉｉｉ因子変異体
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
DK3400002T3 (da) 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205506T1 (de) * 1995-06-12 2001-09-15 Sanquin Bloedvoorziening Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
PT1095143E (pt) * 1998-05-08 2008-11-28 Sanquin Bloedvoorziening Inibidor para o diagnóstico e tratamento de doentes com hemofilia a
EP1129186B2 (de) * 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen

Also Published As

Publication number Publication date
WO2003093313A3 (en) 2004-07-29
CA2484155A1 (en) 2003-11-13
JP2005535588A (ja) 2005-11-24
US8586538B2 (en) 2013-11-19
DK1497330T3 (da) 2010-06-14
ATE463514T1 (de) 2010-04-15
DE60332011D1 (de) 2010-05-20
WO2003093313A2 (en) 2003-11-13
CA2484155C (en) 2015-10-13
EP1497330B1 (en) 2010-04-07
JP2010202664A (ja) 2010-09-16
AU2003227687A1 (en) 2003-11-17
AU2003227687B2 (en) 2009-10-15
US20080219983A1 (en) 2008-09-11
EP1497330A2 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
ES2343681T3 (es) Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad.
JP6527918B2 (ja) 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
JP7273487B2 (ja) 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法
JP6336522B2 (ja) 細胞取込みが低下した第ｖｉｉｉ因子変異体
TWI573806B (zh) 生物活性胜肽
ES2724778T3 (es) Compuestos procoagulantes y procedimientos de uso de los mismos
EP3793588B1 (en) Methods of treating hemophilia a
ES2292255T5 (es) Polipéptido del factor 8 con actividad de factor 8:C
US20220213200A1 (en) Anti-gpiib/iiia antibodies or uses thereof
BR122016022033B1 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
CN105452289A (zh) 适用于治疗血友病的化合物
EA034050B1 (ru) Модифицированные серпины для лечения нарушений свертываемости крови
EP3065769A1 (en) Procoagulant fusion compound
JP2019516347A (ja) 抗アンチトロンビン単一ドメイン抗体及びそれを含むポリペプチド
US12171802B2 (en) Compositions for inhibiting fibrin-VLDL receptor-dependent inflammation and methods of treatment
DK2616486T3 (en) FACTOR VIII VARIATIONS WITH DISABLED CELLULAR ADMISSION
HK40049026B (en) Methods of treating hemophilia a
HK40049026A (en) Methods of treating hemophilia a
Schaub Inhibitors of Platelet Adhesion: VWF-GP1b/IX and Collagen-GPVI Inhibitors
WO2001058475A1 (en) Regulation of platelet adhesion and aggregation